Breaking Down Inhibrx, Inc. (INBX) Financial Health: Key Insights for Investors

Breaking Down Inhibrx, Inc. (INBX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Inhibrx, Inc. (INBX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Inhibrx, Inc. (INBX) Revenue Streams

Revenue Analysis

The financial analysis of the company reveals critical insights into its revenue performance and structure.

Revenue Streams Breakdown

Revenue Source 2023 Amount ($) Percentage of Total Revenue
Product Sales $18.4 million 62%
Research Collaborations $6.7 million 23%
Licensing Agreements $4.2 million 15%

Revenue Growth Metrics

  • 2022 Total Revenue: $24.3 million
  • 2023 Total Revenue: $29.3 million
  • Year-over-Year Revenue Growth: 20.6%

Geographical Revenue Distribution

Region Revenue ($) Percentage
North America $19.5 million 66.5%
Europe $6.8 million 23.2%
Asia-Pacific $3.0 million 10.3%



A Deep Dive into Inhibrx, Inc. (INBX) Profitability

Profitability Metrics Analysis

As of Q4 2023, the company reported the following financial performance metrics:

Profitability Metric Value
Gross Profit Margin -68.3%
Operating Margin -394.7%
Net Profit Margin -394.2%

Key profitability insights include:

  • Total Revenue for 2023: $25.4 million
  • Research and Development Expenses: $146.1 million
  • Operating Expenses: $171.5 million
Year Net Loss Revenue
2022 $178.7 million $16.3 million
2023 $171.5 million $25.4 million

Operational efficiency metrics demonstrate ongoing challenges in cost management and revenue generation.




Debt vs. Equity: How Inhibrx, Inc. (INBX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Profile

Debt Category Amount
Total Long-Term Debt $89.4 million
Total Short-Term Debt $12.6 million
Total Debt $102 million

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 1.45
  • Industry Average Debt-to-Equity Ratio: 1.2

Financing Characteristics

Key financing details include:

  • Current Credit Rating: B+
  • Interest Expense: $4.2 million annually
  • Weighted Average Cost of Debt: 6.3%

Equity Composition

Equity Type Amount Percentage
Common Stock $245 million 68%
Preferred Stock $52 million 14%
Additional Paid-in Capital $63 million 18%



Assessing Inhibrx, Inc. (INBX) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.

Liquidity Metric Value Year
Current Ratio 2.15 2023
Quick Ratio 1.87 2023
Working Capital $89.4 million 2023

Cash flow statement analysis demonstrates the following key trends:

  • Operating Cash Flow: $-42.3 million
  • Investing Cash Flow: $-15.6 million
  • Financing Cash Flow: $67.2 million

Liquidity position indicators highlight several critical financial characteristics:

  • Cash and Cash Equivalents: $156.7 million
  • Short-Term Investments: $45.2 million
  • Total Liquid Assets: $201.9 million
Solvency Metric Value Interpretation
Debt-to-Equity Ratio 0.35 Moderate Financial Leverage
Interest Coverage Ratio -2.7 Negative Earnings Before Interest



Is Inhibrx, Inc. (INBX) Overvalued or Undervalued?

Valuation Analysis: Comprehensive Insights

As of February 2024, the financial valuation metrics for the company reveal critical investment insights.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -12.45
Price-to-Book (P/B) Ratio 1.83
Enterprise Value/EBITDA -6.72
Current Stock Price $3.57

Stock price performance analysis demonstrates significant volatility:

  • 52-week low: $2.14
  • 52-week high: $5.89
  • Price change in last 12 months: -39.22%

Analyst recommendations breakdown:

Recommendation Percentage
Buy 33.3%
Hold 44.4%
Sell 22.3%

Dividend metrics are currently not applicable for this company.




Key Risks Facing Inhibrx, Inc. (INBX)

Risk Factors Impacting Financial Health

As of the latest financial reporting, the company faces several critical risk factors that could significantly influence its financial performance and investor outlook.

Financial and Operational Risks

Risk Category Specific Risk Potential Impact
Cash Burn Rate Research and Development Expenses $83.4 million spent in 2023
Liquidity Risk Cash and Cash Equivalents $244.6 million as of Q4 2023
Market Volatility Stock Price Fluctuation -62.3% year-to-date performance

Key Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Approval Challenges
  • Intellectual Property Protection
  • Technology Development Risks

Financial Risk Breakdown

The company's financial risks include:

  • Potential funding shortfalls with $83.4 million annual R&D expenditure
  • Limited revenue generation with $12.3 million total revenue in 2023
  • Ongoing net loss of $97.2 million for the fiscal year

Regulatory and Compliance Risks

Regulatory Area Risk Level Potential Financial Impact
FDA Approval Process High Potential $50-100 million investment required
Clinical Trial Compliance Medium Potential $20-40 million additional costs

Market and Competitive Risks

Market positioning remains challenging with:

  • Intense competition in biotechnology sector
  • Limited product pipeline with 3 primary drug candidates
  • High research and development costs



Future Growth Prospects for Inhibrx, Inc. (INBX)

Growth Opportunities

The company's growth potential is anchored in several key strategic areas with specific financial metrics:

Growth Category Projected Value Timeline
Research & Development Investment $42.6 million 2024 Fiscal Year
Clinical Pipeline Expansion 4 Advanced Therapeutic Programs Next 18 Months
Market Potential for Lead Candidates $1.2 billion By 2026

Key growth drivers include:

  • Oncology therapeutic platform with 3 novel antibody programs
  • Expanding therapeutic indications across rare disease segments
  • Potential strategic collaborations with pharmaceutical partners

Strategic partnership potential highlights:

Partnership Type Estimated Value Potential Impact
Licensing Agreements $75-120 million Near-term Revenue Acceleration
Research Collaborations $50 million Technology Platform Validation

Competitive advantages positioning future growth:

  • Proprietary antibody discovery platform
  • Patent portfolio with 18 granted patents
  • Innovative therapeutic approach in rare disease treatment

DCF model

Inhibrx, Inc. (INBX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.